Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6304792 | 1.00 | OPRK1 (0.39) | OPRK1CYP3A4ACHEOPRM1OPRD1 | |
| SCHEMBL8301882 | 0.86 | OPRM1 (0.39) | OPRK1CYP3A4ACHEOPRM1OPRD1 | |
| SCHEMBL13282134 | 0.86 | OPRM1 (0.39) | OPRK1CYP3A4ACHEOPRM1OPRD1 | |
| SCHEMBL28168377 | 0.85 | OPRM1 (0.38) | CYP3A4ACHEOPRM1OPRD1 | |
| SCHEMBL18655444 | 0.83 | LMNA (0.45) | — | |
| SCHEMBL13288278 | 0.82 | OPRM1 (0.43) | OPRK1OPRM1OPRD1 | |
| SCHEMBL10636928 | 0.82 | CYP3A4 (0.41) | CYP3A4 | |
| SCHEMBL10636921 | 0.82 | CYP3A4 (0.41) | CYP3A4 | |
| SCHEMBL28168381 | 0.82 | OPRM1 (0.37) | OPRK1OPRM1OPRD1 | |
| SCHEMBL38327 | 0.81 | L3MBTL1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2241306-A2 | Compound with antioxidant peptides | Henkel AG & Co. KGaA (DE) | 2010-10-20 | — | — | EP | claimed |
| EP-1303186-A4 | MEDICINAL USES OF MU-OPIOID RECEPTOR AGONISTS | CORNELL RES FOUNDATION INC (US) | 2007-02-07 | — | — | EP | claimed |
| US-20070027070-A1 | Medicinal Uses of Mu-Opioid Receptor Agonists | CLINICAL RESEARCH INSTITUTE OF MONTREAL (CA) | 2007-02-01 | — | — | US | claimed |
| EP-1303186-A2 | MEDICINAL USES OF MU-OPIOID RECEPTOR AGONISTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2003-04-23 | — | — | EP | claimed |
| WO-2002005748-A2 | MEDICINAL USES OF MU-OPIOID RECEPTOR AGONISTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2002-01-24 | — | — | WO | claimed |
| EP-4397314-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-117858888-A | Intravitreal mitochondrial targeting peptide prodrugs and methods of use thereof | 艾迪雅生物有限责任公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20240100119-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-28 | — | — | US | disclosed |
| US-11931397-B2 | Methods and compositions for the treatment of Sengers syndrome | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2005072295-A2 | METHODS FOR REDUCING OXIDATIVE DAMAGE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050158373-A1 | Small peptides that are energy-independent, non-endocytotic; nontoxic, peptidase resistant | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-21 | — | — | US | disclosed |
| WO-2005001023-A2 | METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040248808-A1 | Methods for preventing mitochondrial permeability transition | PUBLIC HEALTH SERVICE/NATIONAL INSTITUTES OF HEALTH (NIH) | 2004-12-09 | — | — | US | disclosed |
| WO-2004070054-A2 | METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040029796-A1 | Medicinal uses of mu-opioid receptor agonists | CORNELL RESEARCH FOUNDATION, INC. | 2004-02-12 | — | — | US | disclosed |
| EP-1303186-A2 | MEDICINAL USES OF MU-OPIOID RECEPTOR AGONISTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002005748-A2 | MEDICINAL USES OF MU-OPIOID RECEPTOR AGONISTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | CRYAA, CRYAB, IAPP | OPRK1 3377/4885CYP3A4 4817/4885ACHE 620/4885 |
| US-20240100119-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | OAT, TFAM, OTC | OPRK1 3116/4885CYP3A4 4820/4885ACHE 578/4885 |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | OPRL1, TSG101, NGF | OPRK1 112/4885CYP3A4 4854/4885ACHE 133/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | OPRK1 2169/4885CYP3A4 4833/4885ACHE 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.